Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	336.73M +25.6%
Revenue (ttm)	2.01M -81.9%
Net Income	-44.29M
EPS	-7.76
Shares Out	6.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,250
Open	53.70
Previous Close	53.70
Day's Range	52.20 - 54.30
52-Week Range	44.10 - 89.20
Beta	0.56
Analysts	Strong Buy
Price Target	91.90 (+73.4%)
Earnings Date	Nov 19, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratito...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 82
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2025, WSE:CTX's revenue was 4.66 million, a decrease of -70.55% compared to the previous year's 15.83 million. Losses were -42.00 million, 9.29% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for CTX stock is "Strong Buy." The 12-month stock price target is zł 91.90, which is an increase of 73.40% from the latest price.

Price Target

zł 91.90

(73.40% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error